PE20200734A1 - Anticuerpos anti-tgf-beta y su uso - Google Patents
Anticuerpos anti-tgf-beta y su usoInfo
- Publication number
- PE20200734A1 PE20200734A1 PE2019001465A PE2019001465A PE20200734A1 PE 20200734 A1 PE20200734 A1 PE 20200734A1 PE 2019001465 A PE2019001465 A PE 2019001465A PE 2019001465 A PE2019001465 A PE 2019001465A PE 20200734 A1 PE20200734 A1 PE 20200734A1
- Authority
- PE
- Peru
- Prior art keywords
- tgf
- antibody
- seq
- conditions
- beta antibodies
- Prior art date
Links
- 108010047041 Complementarity Determining Regions Proteins 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 101500025614 Homo sapiens Transforming growth factor beta-1 Proteins 0.000 abstract 1
- 101500025624 Homo sapiens Transforming growth factor beta-2 Proteins 0.000 abstract 1
- 101500026551 Homo sapiens Transforming growth factor beta-3 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 abstract 1
- 102000011117 Transforming Growth Factor beta2 Human genes 0.000 abstract 1
- 102000056172 Transforming growth factor beta-3 Human genes 0.000 abstract 1
- -1 autoimmune diseases Chemical compound 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Un anticuerpo monoclonal aislado que se une especificamente a TGF-beta1, TGF-beta2 y TGF-beta3 humanos que comprende las regiones determinantes de la complementariedad (CDR)1-3 de la cadena pesada en la SEQ ID NO:1 y las CDR1-3 de la cadena ligera en la SEQ ID NO:2, en la que el anticuerpo comprende una region constante de IgG4 humana que tiene una prolina en la posicion 228 (numeracion EU), util en el tratamiento de afecciones que estan mediadas por TGF-beta, incluyendo enfermedades autoinmunitarias, afecciones fibroticas y canceres. Tambien se proporcionan usos y usos del anticuerpo junto con otros agentes inmunomoduladores tales como un anticuerpo anti-PD-1.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762448800P | 2017-01-20 | 2017-01-20 | |
| EP17305061 | 2017-01-20 | ||
| PCT/IB2018/000088 WO2018134681A1 (en) | 2017-01-20 | 2018-01-19 | Anti-tgf-beta antibodies and their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20200734A1 true PE20200734A1 (es) | 2020-07-23 |
Family
ID=61656071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019001465A PE20200734A1 (es) | 2017-01-20 | 2018-01-19 | Anticuerpos anti-tgf-beta y su uso |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US10766955B2 (es) |
| JP (3) | JP7213186B2 (es) |
| CN (2) | CN110520441B8 (es) |
| AU (2) | AU2018209391B2 (es) |
| BR (1) | BR112019014787A2 (es) |
| CA (1) | CA3050845A1 (es) |
| CL (1) | CL2019002011A1 (es) |
| CO (1) | CO2019008946A2 (es) |
| CR (1) | CR20190375A (es) |
| DO (1) | DOP2019000191A (es) |
| EC (1) | ECSP19059553A (es) |
| IL (3) | IL268112B2 (es) |
| MA (1) | MA47311A (es) |
| MX (2) | MX2019008551A (es) |
| MY (1) | MY200751A (es) |
| NZ (1) | NZ796440A (es) |
| PE (1) | PE20200734A1 (es) |
| PH (1) | PH12019501635A1 (es) |
| SG (1) | SG11201906660TA (es) |
| TW (3) | TW202506185A (es) |
| UY (1) | UY37575A (es) |
| ZA (1) | ZA201904494B (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR110755A1 (es) | 2017-01-20 | 2019-05-02 | Genzyme Corp | Anticuerpos dirigidos a hueso |
| TW202506185A (zh) | 2017-01-20 | 2025-02-16 | 法商賽諾菲公司 | 抗TGF-β抗體及其用途 |
| SG11202012991QA (en) * | 2018-07-10 | 2021-01-28 | Sanofi Sa | Combination therapies against cancer targeting cd38 and tgf-beta |
| NZ772550A (en) | 2018-08-30 | 2025-08-29 | Immunitybio Inc | Multi-chain chimeric polypeptides and uses thereof |
| KR20210069639A (ko) | 2018-08-30 | 2021-06-11 | 에이치씨더블유 바이올로직스, 인크. | 단일-사슬 키메라 폴리펩타이드 및 이의 용도 |
| EP3897689B1 (en) * | 2018-12-21 | 2025-02-05 | Northwestern University | Use of annexins in preventing and treating muscle membrane injury |
| EP3739588A1 (en) * | 2019-05-13 | 2020-11-18 | Koninklijke Philips N.V. | Assessment of multiple signaling pathway activity score in airway epithelial cells to predict airway epithelial abnormality and airway cancer risk |
| US11738052B2 (en) | 2019-06-21 | 2023-08-29 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
| CN115362169A (zh) | 2020-02-11 | 2022-11-18 | Hcw生物科技公司 | 色谱树脂以及其用途 |
| CA3169231A1 (en) | 2020-02-11 | 2021-08-19 | HCW Biologics, Inc. | Methods of treating age-related and inflammatory diseases |
| EP4103599A1 (en) | 2020-02-11 | 2022-12-21 | HCW Biologics, Inc. | Methods of activating regulatory t cells |
| US12497462B2 (en) | 2020-04-29 | 2025-12-16 | Immunitybio, Inc. | Anti-CD26 proteins and uses thereof |
| CN113563473A (zh) | 2020-04-29 | 2021-10-29 | 三生国健药业（上海）股份有限公司 | 四价双特异性抗体、其制备方法和用途 |
| US12024545B2 (en) | 2020-06-01 | 2024-07-02 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| US20220119513A1 (en) * | 2020-06-08 | 2022-04-21 | Zoetis Services Llc | Anti-tgfb antibodies and therapeutic uses thereof |
| CN112940119B (zh) * | 2021-04-26 | 2022-05-20 | 北京芳渟阳生生物科技有限公司 | 一种单克隆抗体及其与间充质干细胞外泌体的联合应用 |
| WO2022266510A1 (en) * | 2021-06-18 | 2022-12-22 | Genzyme Corporation | Anti-tgf-beta antibody formulations and their use |
| AU2022325953B2 (en) | 2021-08-11 | 2025-12-18 | Immunitybio, Inc. | Multi-chain chimeric polypeptides and use thereof in the treatment of liver diseases |
| CN115707716A (zh) * | 2021-08-18 | 2023-02-21 | 丹生医药技术(上海)有限公司 | 一种TGF-β/VEGF双功能抗体融合蛋白 |
| JP2024542026A (ja) * | 2021-11-01 | 2024-11-13 | ジェンザイム・コーポレーション | 骨形成不全症の治療 |
| US20230372444A1 (en) | 2022-04-13 | 2023-11-23 | HCW Biologics, Inc. | Methods of reducing neuroinflammation |
| KR20250004747A (ko) | 2022-04-13 | 2025-01-08 | 이뮤니티바이오, 인크. | 생체 시계 유전자 장애의 치료에 사용하기 위한 다중-사슬 키메라 폴리펩티드 |
| CN115508565B (zh) * | 2022-10-20 | 2024-11-15 | 成都医学院第一附属医院 | Cilp1作为肾纤维化生物标志物的应用 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4867973A (en) | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
| US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| US5571714A (en) | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
| DE69329974T2 (de) | 1992-12-04 | 2001-07-19 | Medical Research Council, London | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| US5824655A (en) | 1995-02-15 | 1998-10-20 | The University Of Utah | Anti-transforming growth factor-β gene therapy |
| GB9601081D0 (en) | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
| CN1300173C (zh) | 1996-02-09 | 2007-02-14 | 艾博特生物技术有限公司 | 结合人TNFα的人抗体 |
| WO1998035703A2 (en) | 1997-02-14 | 1998-08-20 | The Salk Institute For Biological Studies | Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents |
| MY131805A (en) | 1997-09-18 | 2007-09-28 | Biogen Idec Inc | Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis. |
| EP1074563A1 (en) | 1999-08-02 | 2001-02-07 | F. Hoffmann-La Roche Ag | Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof |
| US20020063763A1 (en) | 2000-11-29 | 2002-05-30 | Mantell David Allen | Apparatus and method for removing air bubbles from an ink jet printhead |
| US20030224501A1 (en) | 2000-03-17 | 2003-12-04 | Young Paul E. | Bone morphogenic protein polynucleotides, polypeptides, and antibodies |
| BR0317896A (pt) | 2002-12-31 | 2005-12-06 | Altus Pharmaceuticals Inc | Complexos de cristais de proteìna e polìmeros iÈnicos |
| EP1620128A1 (en) | 2003-04-30 | 2006-02-01 | Genzyme Corporation | Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency |
| EP1646655A2 (en) | 2003-07-09 | 2006-04-19 | Eli Lilly And Company | Tgf-beta1 ligands |
| WO2005097832A2 (en) | 2004-03-31 | 2005-10-20 | Genentech, Inc. | Humanized anti-tgf-beta antibodies |
| ES2887039T3 (es) | 2004-04-21 | 2021-12-21 | Alexion Pharma Inc | Conjugados para administración ósea y procedimiento de uso de estos para dirigir proteínas al hueso |
| ES2905923T3 (es) | 2005-02-08 | 2022-04-12 | Genzyme Corp | Anticuerpos de TGFbeta |
| TW200714289A (en) | 2005-02-28 | 2007-04-16 | Genentech Inc | Treatment of bone disorders |
| US20100267934A1 (en) | 2007-05-31 | 2010-10-21 | Genmab A/S | Stable igg4 antibodies |
| BRPI0821906B1 (pt) | 2008-01-03 | 2022-06-07 | The Scripps Research Institute | Anticorpo isolado de comprimento total, seu uso, polinucleotideo, vetor, e célula hospedeira |
| US8574577B2 (en) | 2008-01-03 | 2013-11-05 | The Scripps Research Institute | VEGF antibodies comprising modular recognition domains |
| JP5798919B2 (ja) | 2008-08-25 | 2015-10-21 | アンプリミューン、インコーポレーテッドＡｍｐｌｉｍｍｕｎｅ， Ｉｎｃ． | Ｐｄ−１アンタゴニストの組成物および使用方法 |
| CA2745317C (en) | 2008-12-22 | 2019-03-05 | Ida Hilden | Antibodies against tissue factor pathway inhibitor |
| JP2012524818A (ja) | 2009-04-24 | 2012-10-18 | バンダービルト ユニバーシティ | 骨細胞機能および骨成長の抗ＴＧＦ−βによる誘導法 |
| ES2638521T5 (es) | 2010-03-05 | 2021-03-02 | Univ Johns Hopkins | Composiciones y métodos para anticuerpos y proteínas de fusión inmunomoduladores dirigidos contra dianas |
| FI2691417T4 (fi) | 2011-03-29 | 2025-01-14 | Roche Glycart Ag | Vasta-aineen Fc-variantteja |
| PL2699264T3 (pl) | 2011-04-20 | 2018-08-31 | Medimmune, Llc | Przeciwciała i inne cząsteczki wiążące B7-H1 i PD-1 |
| LT2714735T (lt) | 2011-06-03 | 2021-12-10 | Xoma Technology Ltd. | Tgf beta specifiniai antikūnai |
| NZ619524A (en) | 2011-06-13 | 2016-10-28 | Abgenomics Cooperatief Ua | Anti-psgl-1 antibodies and uses thereof |
| KR20140084201A (ko) | 2011-10-19 | 2014-07-04 | 알렉시온 파마 홀딩 | 알칼리성 포스파타제 및/또는 나트륨이뇨 펩티드를 포함하는 조성물 및 그의 사용 방법 |
| US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
| US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| MX361773B (es) | 2012-05-31 | 2018-12-17 | Innate Pharma | Agentes de ligación a tlr3. |
| US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| WO2014062978A1 (en) * | 2012-10-17 | 2014-04-24 | Cedars-Sinai Medical Center | Molecular signatures of ovarian cancer |
| SI2976359T2 (sl) * | 2013-03-20 | 2022-05-31 | Genzyme Corporation | Postopki zdravljenja imperfektne osteogeneze |
| DK2981822T3 (da) | 2013-05-06 | 2020-12-07 | Scholar Rock Inc | Sammensætninger og fremgangsmåder til vækstfaktormodulation |
| PL3702373T3 (pl) | 2013-09-13 | 2022-12-05 | Beigene Switzerland Gmbh | Przeciwciała anty-PD1 i ich zastosowanie jako środki terapeutyczne i diagnostyczne |
| CA2933883A1 (en) * | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies |
| TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| EP3119419B1 (en) | 2014-03-17 | 2019-04-03 | Piotr Jachimczak | Combination for use in a method of treating cancer |
| CN107428825A (zh) | 2014-10-10 | 2017-12-01 | 创祐生技股份有限公司 | 治疗及/或预防肿瘤生长、侵袭及/或转移的方法 |
| PE20171067A1 (es) * | 2014-10-14 | 2017-07-24 | Novartis Ag | Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| HK1247861A1 (zh) | 2015-01-30 | 2018-10-05 | President And Fellows Of Harvard College | 用於癌症治疗的肿瘤周围和肿瘤内部材料 |
| TWI733661B (zh) | 2015-03-04 | 2021-07-21 | 美商健臻公司 | 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體 |
| US10167334B2 (en) | 2015-04-03 | 2019-01-01 | Xoma Technology Ltd. | Treatment of cancer using anti-TGF-BETA and PD-1 antibodies |
| KR102740444B1 (ko) | 2015-04-17 | 2024-12-10 | 브리스톨-마이어스 스큅 컴퍼니 | 항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물 |
| WO2017011773A2 (en) | 2015-07-15 | 2017-01-19 | Modernatx, Inc. | Codon-optimized nucleic acids encoding antibodies |
| EP3344660B1 (en) | 2015-08-31 | 2025-03-05 | National Research Council of Canada | Tgf-beta-receptor ectodomain fusion molecules and uses thereof |
| US20190216943A1 (en) | 2016-08-11 | 2019-07-18 | Precithera, Inc. | Tgf-beta antagonist conjugates |
| TW202506185A (zh) | 2017-01-20 | 2025-02-16 | 法商賽諾菲公司 | 抗TGF-β抗體及其用途 |
| AR110755A1 (es) | 2017-01-20 | 2019-05-02 | Genzyme Corp | Anticuerpos dirigidos a hueso |
-
2018
- 2018-01-18 TW TW113140547A patent/TW202506185A/zh unknown
- 2018-01-18 TW TW107101789A patent/TWI787230B/zh active
- 2018-01-18 TW TW111145565A patent/TWI856437B/zh active
- 2018-01-19 JP JP2019539214A patent/JP7213186B2/ja active Active
- 2018-01-19 NZ NZ796440A patent/NZ796440A/en unknown
- 2018-01-19 SG SG11201906660TA patent/SG11201906660TA/en unknown
- 2018-01-19 IL IL268112A patent/IL268112B2/en unknown
- 2018-01-19 US US15/875,532 patent/US10766955B2/en active Active
- 2018-01-19 PE PE2019001465A patent/PE20200734A1/es unknown
- 2018-01-19 CN CN201880007975.3A patent/CN110520441B8/zh active Active
- 2018-01-19 BR BR112019014787-0A patent/BR112019014787A2/pt unknown
- 2018-01-19 CR CR20190375A patent/CR20190375A/es unknown
- 2018-01-19 MX MX2019008551A patent/MX2019008551A/es unknown
- 2018-01-19 CA CA3050845A patent/CA3050845A1/en active Pending
- 2018-01-19 MY MYPI2019003989A patent/MY200751A/en unknown
- 2018-01-19 UY UY0001037575A patent/UY37575A/es not_active Application Discontinuation
- 2018-01-19 IL IL311866A patent/IL311866B1/en unknown
- 2018-01-19 CN CN202311230922.7A patent/CN117417939A/zh active Pending
- 2018-01-19 AU AU2018209391A patent/AU2018209391B2/en active Active
- 2018-01-19 MA MA047311A patent/MA47311A/fr unknown
-
2019
- 2019-07-09 ZA ZA2019/04494A patent/ZA201904494B/en unknown
- 2019-07-12 PH PH12019501635A patent/PH12019501635A1/en unknown
- 2019-07-17 MX MX2023002588A patent/MX2023002588A/es unknown
- 2019-07-18 CL CL2019002011A patent/CL2019002011A1/es unknown
- 2019-07-19 DO DO2019000191A patent/DOP2019000191A/es unknown
- 2019-08-16 CO CONC2019/0008946A patent/CO2019008946A2/es unknown
- 2019-08-19 EC ECSENADI201959553A patent/ECSP19059553A/es unknown
-
2020
- 2020-07-16 US US16/931,198 patent/US11242384B2/en active Active
-
2021
- 2021-12-23 US US17/561,510 patent/US12049496B2/en active Active
-
2023
- 2023-01-13 JP JP2023003484A patent/JP7411832B2/ja active Active
- 2023-12-22 JP JP2023216508A patent/JP2024038040A/ja active Pending
-
2024
- 2024-07-09 US US18/767,270 patent/US20250026821A1/en active Pending
- 2024-11-13 AU AU2024264593A patent/AU2024264593A1/en active Pending
-
2025
- 2025-10-05 IL IL323799A patent/IL323799A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20200734A1 (es) | Anticuerpos anti-tgf-beta y su uso | |
| EA201991729A1 (ru) | Антитела к tgf-бета и их применение | |
| CL2023002239A1 (es) | Anticuerpos de b7-h4 y métodos para usarlos | |
| AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
| CO2021007956A2 (es) | Anticuerpo humanizado anti-pd-1 humana | |
| PE20211887A1 (es) | Receptor antigenico quimerico (car) que comprende un dominio de union a antigenos, el cual se une selectivamente a la region constante del tcr beta 1 (trbc1) o trbc2 de celulas t | |
| PE20200384A1 (es) | Metodo de fabricacion de anticuerpos bispecificos, anticuerpos bispecificos y uso terapeutico de dichos anticuerpos | |
| MX2017006323A (es) | Anticuerpos que comprenden regiones constantes pesadas modificadas. | |
| EA202092410A1 (ru) | Конъюгаты камптотецина с пептидом | |
| CO2020010277A2 (es) | Moléculas de unión a antígeno dirigidas a her2 que comprenden 4-1bbl | |
| PE20190208A1 (es) | Anticuerpos que reconocen tau | |
| PE20181451A1 (es) | Anticuerpos neutralizadores del virus de inmunodeficiencia humana | |
| PE20121649A1 (es) | Anticuerpos monoclonales frente a progastrina y sus usos | |
| PE20240111A1 (es) | Moleculas de union a pd-1 y metodos de uso de las mismas | |
| PE20190737A1 (es) | Anticuerpos anti-cd27 | |
| PE20191759A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos | |
| UY36194A (es) | Anticuerpos anti-tau humanizados | |
| MX2016008472A (es) | Anticuero monoclonal neutralizador de anti-il-33-humana. | |
| PE20141908A1 (es) | Anticuerpos cd47 y metodos de uso los mismos | |
| PE20191031A1 (es) | ANTICUERPOS ANTI-C1s Y METODOS DE USO DE LOS MISMOS | |
| PE20171180A1 (es) | Anticuerpos anti-pd-1 y sus metodos de uso | |
| UY36942A (es) | Proteínas de unión a antígeno que activan el receptor de leptina | |
| MX2019013132A (es) | Anticuerpos que comprenden regiones constantes pesadas modificadas. | |
| AR096895A2 (es) | Anticuerpo que se une a la citoquina, linfopoyetina estromal tímica (tslp) | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos |